BOSTON–(BUSINESS WIRE)–GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced that it will present at the 2022 BIO CEO & Investor Conference.
Daniel J. Mandell, PhD, Co-founder and Chief Executive Officer of GRO Biosciences, will provide an overview of the company’s platform and corporate strategy, as well as the advancement of DuraLogic™ and ProGly™ platform chemistries in protein therapeutics. The presentation is scheduled for February 14, 2022, at 2:30 p.m. ET.
The presentation will be given in-person at the New York Marriott Marquis. Register to access the GRObio presentation and the entire conference on the BIO CEO & Investor Conference event website.
To arrange a meeting with GRObio leadership, contact Tad Stewart, GRObio’s Chief Business Officer via email at email@example.com.
About GRO Biosciences
GRO Biosciences (“GRObio”) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Company’s NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by Dr. George Church of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn, Twitter, Instagram, Facebook and the web at grobio.com.
Investor & Partnering Contact: